Peter Voorhees, MD | Authors


Pomalidomide-Based Triplets Improve Responses in Relapsed/Refractory Multiple Myeloma

August 14, 2019

Peter Voorhees, MD, discusses the latest data for the use of pomalidomide-containing regimens for the treatment of patients with relapsed/refractory multiple myeloma. He highlights data from 2 randomized clinical trials that demonstrated an improvement in responses with pomalidomide-based triplets.

Rationale for Adding Daratumumab to RVd in Multiple Myeloma

December 14, 2018

Peter Voorhees, MD, investigator, department of hematologic oncology & blood disorders, Levine Cancer Institute/Atrium Health, discusses the rationale for adding daratumumab to triplet regimen bortezomib, lenalidomide, and dexamethasone in patients with multiple myeloma.

Daratumumab for the Treatment of Patients With Multiple Myeloma

July 06, 2015

Peter Voorhees, MD, associate professor, School of Medicine, UNC-Chapel Hill, Clinical Research, Leukemia, Lymphoma, and Myeloma Program, UNC Lineberger Comprehensive Cancer Center, discusses a phase II study examining daratumumab for the treatment of patients with multiple myeloma.